Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&DLisa Taylor Ash joins Board of Directors, ...
Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...
The potential benefits of organoids for fundamental research and medicine are huge. Efforts to establish proper boundaries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results